3 data and information 3 - update, page-86

re: 3. alzheimer's drug shows cont. promise in ext The drug discussed PBT-1 is merely a forerunner to the more powerful drug PBT-2 to be used in a trial later this year.

PBT's comment on the new drug PBT-2:
“We have designed compounds that are superior to PBT-1.

"PBT-2 is a small molecular weight chemical entity that demonstrates a significant improvement on PBT-1.

PBT-2 has characteristics appropriate for oral bioavailability and blood brain barrier permeability. PBT-2 exceeds PBT-1 in both pre-clinical in-vitro and in vivo-testing".
______________________________________

1. The advantage of small Molecular size.
Comment: It is clear that a small weight chemical entity is preferred to a larger molecule;

Smaller molecules can penetrate membranes or other obstacles and hence get faster to the destination.
More of the dosage arrives at the sourse of the problem and this means that one could use less compared with a drug with a larger molecule.

The faster a drug arrives at the problem spot, the more efficient a dosage is. Much of the drug with larger molecules is absorbed by the body before it can be used.

Info on PBT:

http://www.hotcopper.com.au/post_thread.asp?fid=1&tid=54324#136282

Gerry
Readers, please do your own research and you decide if and when to buy, hold or sell any stocks.